May 2026 Research Update

Across these papers, oral migalastat was linked to lower Fabry-related blood markers and overall stability of kidney and heart measurements in adults who had gene variants expected to respond, although some people still had progression or could not tolerate it. Two small studies looked at add-on medicines often used for kidney or heart problems: one suggested lower protein in the urine and weight loss over 6 months, while the other did not show clear heart-related benefit after adjusting for differences between patients. [1] [2] [3]

In an 87-person, single-center retrospective cohort followed for up to 8 years, migalastat lowered plasma lyso-Gb3 (a blood marker related to Fabry storage) in both treatment-naive patients and those who switched from enzyme replacement therapy. Kidney function was largely preserved at the group level, and there was no progression to end-stage kidney disease reported, but some patients had worsening over time and a small number stopped treatment due to side effects. [1]

In the same real-world migalastat cohort, heart structure and rhythm measurements were mostly stable, and left ventricular mass index fell in the switch group when the analysis was restricted to genotypes classified as amenable. The QTc interval increased in the switch group but stayed within normal or only mildly prolonged ranges in this report. [1]

One case report described a 37-year-old woman whose corneal deposits improved after a year of migalastat, returned when treatment was paused during pregnancy, and then nearly disappeared again after restarting, with vision remaining normal. Because this is a single patient, it cannot show what will happen for most people or across different eye findings. [4]

In a 15-person prospective proof-of-concept study in overweight, non-diabetic Fabry patients with ongoing protein in the urine despite optimized background therapy, adding tirzepatide for 6 months was linked to lower 24-hour proteinuria and lower body mass index, while estimated kidney function stayed stable. Heart-related blood markers (NT-proBNP and high-sensitivity troponin T) also decreased, but there were no structural changes on echocardiography over this short follow-up. [2]

In a separate retrospective study of 99 Fabry patients (15 receiving SGLT2 inhibitors, about 663 days follow-up), side effects like frequent urination and low volume symptoms were common, but only two people stopped the medication. After propensity score matching (13 vs 13), there were no significant differences in heart ultrasound measures or lab markers between those who did and did not receive an SGLT2 inhibitor, so clinical benefit remained uncertain in this dataset. [3]

For patients and caregivers, these studies mainly add real-world context about what changes have been seen over time with migalastat in adults with amenable variants, including biomarker reductions and generally stable kidney and heart measurements, along with the possibility of intolerance or progression in some individuals. The add-on medicine studies are early and small: tirzepatide was linked to less protein in the urine and weight loss over 6 months in a specific group (overweight, non-diabetic patients with persistent proteinuria), while SGLT2 inhibitors appeared reasonably tolerable but did not show clear heart benefit after matching. Larger, longer, and more controlled studies would be needed to know how reliably these add-on approaches change long-term kidney, heart, eye, or quality-of-life outcomes.

Across these early-stage studies, researchers explored gene-based approaches aimed at addressing Fabry disease at its source: increasing alpha-galactosidase A (the missing or reduced enzyme) and reducing the buildup of GL-3 (also called Gb3) in cells. The overall direction was consistent, with both studies reporting lower stored fat in target cells after treatment, but both are preclinical and do not show how well these strategies work in people. [5] [6]

In a mouse model of Fabry disease, an intravenous gene therapy vector (AAV9 carrying the human GLA gene) was linked to markedly lower GL-3 in several kidney cell types, including podocytes, endothelial cells, and tubular epithelial cells, measured 8 weeks after treatment. The researchers also detected AAV9 particles inside podocytes using specialized electron microscopy methods, which supports the idea that the treatment reached these kidney cells. The authors noted technical limitations and that the exact cell-by-cell mechanism still needs more study. [6]

In a laboratory cell study using Fabry endothelial cells, researchers tested nanoparticles designed to deliver two different genetic tools at once: a GLA plasmid (to increase alpha-galactosidase A activity) and a small interfering RNA (siRNA) that lowered Gb3 synthase (a protein involved in making Gb3). The combined approach increased alpha-galactosidase A activity compared with untreated cells and lowered Gb3-related measures, with effects on Gb3 lasting up to 15 days in the lab. Alpha-galactosidase A activity was generally similar to the plasmid-only approach, while some combined formulations produced greater reductions in Gb3-related measures. Cell viability stayed at or above 80% in tested formulations, while some formulations showed blood-compatibility issues such as cell clumping that was reduced by changing the nanoparticle coating. [5]

These studies are background research that helps explain what scientists are trying next beyond current Fabry treatments, especially approaches that aim to increase enzyme function and reduce storage in key organs like the kidney. Because one study was in mice and the other was only in cells, important questions remain unanswered, including how long effects would last in people and what safety issues might arise outside the lab. For now, the main value is understanding the types of gene-based strategies being tested and what they have shown in early experiments. [5] [6]

Across these studies, blood-based markers were used to estimate future health risks in Fabry disease, especially the chance of developing heart problems and whether a child is more likely to have a later-onset form. Overall, established and newer markers showed patterns that could help sort people into higher- and lower-risk groups, but the newer approaches still need confirmation in broader, real-world settings. [7] [8] [9]

In a small, retrospective follow-up of 25 newborn-screened boys, the blood marker lyso-Gb3 rose early and then leveled off in those with later-onset genetic variants, while it stayed much lower and more stable in boys with variants of uncertain significance. The study also reported overlap in lyso-Gb3 levels at birth between groups, which limits how well a single newborn result can separate these groups on its own. [7]

A separate study used a high-throughput approach to measure many proteins in the blood and proposed a 10-protein signature that separated Fabry patients with cardiovascular involvement from those without. The proteins in this signature pointed to a combination of mitochondrial stress, lysosome-related changes, blood vessel remodeling, and immune activation as part of Fabry heart disease. [8]

In a biomarker study that compared 60 people with Anderson-Fabry disease and 60 healthy controls, the blood microRNA miR-19a-3p was lower in Fabry disease and was also lower in those with Fabry-related cardiomyopathy. Lower miR-19a-3p levels tracked with more severe heart injury, and in statistical modeling, higher miR-19a-3p was independently associated with less cardiac damage. [9]

For patients and families, these papers show how blood tests are being studied not just to confirm Fabry disease, but also to estimate likely disease course (such as later-onset patterns in newborn-screened boys) and the risk of heart involvement. Right now, lyso-Gb3 has the most concrete longitudinal data in presymptomatic children in this set, while the 10-protein panel and miR-19a-3p results are best viewed as research aimed at improving risk grouping and understanding heart involvement. Key uncertainties include how well these newer markers perform across different ages, sexes, genetic variants, and clinics, and whether they add clear value beyond existing clinical evaluation and commonly used heart-related blood tests. [7] [8] [9]

Across these papers, a clearer picture emerges that heart rhythm problems in Fabry disease have both practical risk markers seen in patient follow-up and deeper biological drivers seen in lab models. A real-world cohort study suggested that certain easily described features help separate lower from higher risk over time, while a cell-based study pointed to broad changes in electrical signaling genes that may help explain why rhythm instability can occur. [10] [11]

In a retrospective multicenter cohort of 160 adults in the French Heart Fabry cohort, two factors stood out as independent predictors of major arrhythmic events: non-sustained ventricular tachycardia (short runs of a fast rhythm from the lower heart chambers) and age over 55. Over 5 years after diagnosis, the estimated incidence of major arrhythmic events ranged from 1.8% with 0 risk factors to 44.4% with 2 risk factors. [10]

In an exploratory lab study using Fabry disease patient-derived induced pluripotent stem cell ventricular heart muscle cells, arrhythmias were seen in all Fabry cell samples tested and in none of the control samples. The Fabry cells also showed slower electrical conduction and widespread differences in the activity of genes involved in sodium, potassium, and calcium channels, which are key parts of how the heart generates and conducts electrical signals. [11]

When the researchers restored activity of the GLA gene in the lab model using an adenovirus approach, the arrhythmia pattern did not improve and gene activity changes were only partly corrected. This suggests that, at least in this simplified lab system, rhythm instability may not be fully reversed by restoring this single gene alone, or may require additional factors not present in the model. [11]

For patients and caregivers, this group of studies mainly adds context for why rhythm monitoring and risk discussions in Fabry disease can vary from person to person. One study in adults helps describe which features tracked with higher rates of serious rhythm events over 5 years, while the lab study is background research that may help explain underlying causes (changes in the heart cells' electrical wiring) but does not directly predict an individual person's risk. Important uncertainties remain, including how well the lab model reflects real hearts and how these biological changes connect to day-to-day clinical outcomes across diverse Fabry populations. [10] [11]

Together, these studies show that Fabry disease family genetics can come into focus at two time points: before pregnancy (carrier screening) and at birth (newborn screening). A key theme is that test choice matters: DNA-based approaches can detect risk that enzyme-only screening may miss, especially in females. Another theme is that some families may carry rare GLA gene changes where combining clinical information, lab testing, and tissue studies helps clarify whether the change truly causes Fabry disease. [12] [13] [14]

In a pilot implementation study in Spain, preconception carrier screening using a large multi-gene sequencing panel found that 62% of screened individuals carried at least one disease-causing gene change, and 4% of couples were identified as being at reproductive risk for several conditions that included Fabry disease (GLA). In the subset with follow-up after results disclosure, most couples pursued reproductive options such as in vitro fertilization with preimplantation genetic testing or prenatal diagnosis, supporting feasibility of offering this kind of screening in a public health setting. [12]

Using Fabry Registry data and Tennessee newborn screening data, a retrospective analysis found large sex differences among people detected through newborn screening: females had higher remaining alpha-galactosidase enzyme activity than males (for example, leukocyte median 45.9% vs 3.9%). Females also had later symptom onset and later diagnosis, and were less likely to start Fabry-specific treatment, while Tennessee newborn screening identified 25 males and no females, highlighting limitations of enzyme-based newborn screening for females. The authors suggested sex-specific screening cutoffs or adding genetic sequencing to reduce missed cases. [13]

A separate study focused on one newly described GLA missense change (c.227T>A; p.Met76Lys) within a family where Fabry disease presented mainly as heart involvement. In 28 patients studied with a mix of clinical data, heart tissue testing, and lab models, the variant was linked to reduced enzyme function and heart muscle changes on biopsy (including scarring), supporting that it can be disease-causing; in cell experiments, the drug migalastat partially restored enzyme activity. This type of work helps sort out whether a specific family variant is harmful and whether lab testing suggests it may respond to certain therapies, while still being limited by small numbers and reliance on laboratory models. [14]

For families affected by Fabry disease, these papers add context about how inherited risk may be identified at different life stages and why results can differ by sex and by testing method. The newborn screening study suggests that enzyme-only screening may miss females, which is important background when interpreting how Fabry disease is found in families, but it does not establish a single best screening approach. The variant study shows why some genetic results need careful confirmation using multiple types of evidence, because a rare family-specific gene change can be hard to interpret from DNA alone. Overall, the research highlights ongoing uncertainty about the most accurate and equitable screening strategies, especially for females and for rare genetic variants. [12] [13] [14]

Together, these papers reinforce that Fabry disease can affect multiple body systems, and that symptoms may broaden over time. One regional study showed nerve-related symptoms were common and that more organs were involved at older ages, while a separate small study linked balance and eye-movement problems with higher levels of certain inflammation signals in the blood. [15] [16]

In a descriptive study of 69 people with Fabry disease from the Coquimbo Region of Chile, peripheral nervous system involvement was reported in 71%, with kidney involvement in 39.1%. The number of body systems affected was higher at older ages, and older patients were more likely to be using multiple long-term medicines, suggesting symptom burden can build over time. [15]

In a prospective observational study of 40 people with Fabry disease, those with vestibulo-oculomotor dysfunction (problems coordinating balance and eye movements) had higher levels of several inflammatory cytokines in their blood, including IL-2, IL-17A, and TNF-beta. Higher TNF-beta levels were also linked to slower and less accurate rapid eye movements, and higher IL-12p70 levels were seen in people with defective smooth pursuit (a type of tracking eye movement). [16]

One education study suggests that recognizing Fabry as a possible cause of heart thickening may depend on clinician training and standardized pathways. After a blended learning program, cardiologists improved their ability to correctly identify rare causes of left ventricular hypertrophy (heart muscle thickening), including Fabry disease, in case-based assessments. [17]

For patients and caregivers, this group of studies mainly adds context about the range of places Fabry can show up in the body (nerves, kidneys, and possibly balance/eye-movement systems) and how symptom patterns may change with age. The inflammation results are early and based on a small study, so it is not clear yet how well these blood signals explain day-to-day symptoms or whether they are useful for monitoring. The education study is background evidence that clinician awareness can influence recognition of Fabry-related heart thickening, but it does not measure whether patient outcomes improved. [15] [16] [17]